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BRFS was 77% without MF vs 17% with MF (p 0.001) 
BRFS was: PSA 0.2-1: 83%; 1.1-2: 66%; 2.1-10: 39%; >10.1: 
37%. p: 0.02  
 
Conclusion: cPET/TAC detect initial local and regional 
relapses that can be treated with local radiotherapy with or 
without hormonal therapy with good results. 
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Purpose or Objective: To prospectively evaluate the impact 
of Choline/ PSMA PET-CT imaging on management of patients 
with prostate cancer (PC). 
 
Material and Methods: Fifty patients with high risk or 
recurrent PC received a 11Choline and/or a 68Ga-PSMA-PET-
CT before radiation treatment planning within a prospective 
register study. Main subgroups were identified and only 
patients with a conventional staging before PET-CT were 
evaluated to compare treatment management decisions 
before and after PET-CT with regard to treatment intent, 
target volume (TV) definition, radiation dose and duration of 
androgen deprivation therapy (ADT). 
 
Results: The three main subgroups fulfilling the mentioned 
conditions above were high risk (HR, n=17), recurrence after 
prostatectomy (R, n=12) and R plus salvage radiotherapy 
(RSR, n=7). In HRPC, TNM-changes (n=12/17) led to treatment 
changes (n=14) including TV-changes (n=12). In R, TNM-
changes (n=8/12) resulted in treatment changes (n=8) 
including TV-changes (n=7). In the group after RSR, TNM-
changes (n=6/7) resulted in treatment changes (n=6).  
Management was changed in 82% (HRPC), 66%(R) and 
85%(RSR). Of these groups (n=36) only two patients were 
initially stratified as M1. PET-CT led to downstaging (M0) or 
diagnosed only oligometastatic disease enabling curative 
treatment in both patients. However, in 12 patients initially 
planned for curative treatment detection of N1-disease 
(n=3/9) or newly diagnosed M1-disease (n=9/11) shifted 
treatment allocation to palliative therapy.  
Taken together, curative treatment could be offered to 
initially diagnosed M1-patients (n=2). Since patients with RSR 
were usually in the palliative situation, PET-CT enabled in 
further 28% (2/7) of patients disease localization and curative 
treatment. However, of initially curatively planned patients 
(27/29) with R or HRPC, PET-CT facilitated to avoid 
overtreatment in ~30% (8/27) of patients due to early 
visualization of incurable disease. Main limitation is the 
absence of histological verification. 
 
Conclusion: PET-CT had a pronounced impact on decision 
making and management in this group of patients with high-
risk or recurrent prostate cancer. Therefore we suggest that 
PET-CT should be considered in the work-up in specific 
clinical situations. 
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Purpose or Objective: To evaluate the possible impact of 
positive margins (PM) after surgery for prostate cancer on: I) 
biochemical parameters of recurrence (immediate failure 
rate and the time to development of biochemical recurrence) 
and II) the incidence of macroscopic disease at magnetic 
resonance image (MRI) realized before salvage radiation 
therapy (SRT). 
 
Material and Methods: Data from 101 prostate cancer 
patients treated between 2012-13 was analyzed. Fifty (49.5 
%) had MRI before SRT. PSA failure was defined has a value 
greater than 0.2 ng/ml after 6 weeks after prostatectomy. 
Cases with PSA >0.2 at the first measure 6 weeks after the 
surgery were categorized (no vs yes) and considered 
separately for the analysis of immediate failure. Categorical 
analysis were done using chi-square test. The time to the 
development of biochemical recurrence was presented in 
Kaplan Meier and log-Rank test was used to compare PM vs 
negative margins (MN) group. Mann-Whitney-Wilcoxon test 
was used to compare the PSA means between groups (PM vs 
NM / macroscopic recurrence present vs absent). The 
statistical analysis was done using SPSS V.20. 
 
Results: The basic characteristics of this population were: 
age 66.8 years (median), initial PSA 8.0 ng/ml (median), 
52.6% pT2 and 34.7% pT3. The proportions of each 
pathological risk group were 7%, 42% and 51% (low-risk, 
intermediate risk, high-risk) and 43,6% had PM (n=44). Those 
with PM had an increased chance of immediate PSA failure 
(p=0.004) and an earlier development of biochemical 
recurrence (23.4 months vs 49 months, p = 0.001). The mean 
PSA of the recurrence was 1.4 (+/- 1.7) ng/ml vs 2.6 ng/ml 
(+/- 6.1) (p = 0.839), for NM and PM respectively. Patients 
with macroscopic recurrence had a greater pre-SRT PSA: 3.5 
(+/- 1.7) vs 0.8 (+/- 0.7) ng/ml. The incidence of biochemical 
recurrence with prostatic nodule in the MRI was not 
influenced by margin status (p=0.108) and marginally not 
influenced by pathological status (low or intermediate risk vs 
high risk) (p=0.062). 
 
Conclusion: PM patients have had an earlier development of 
biochemical recurrence but our series did not find a 
significant impact of margin status on the incidence of nodule 
on prostatic bed. A possible delay in the detection of the 
recurrence in margin negative patients should be evaluated 
in next studies. 
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Purpose or Objective: Recent evidences has fostered the 
emergence of Stereotactic Body Radiation Therapy (SBRT) as 
a promising treatment modality for the management of 
localized prostate cancer. In fact, given the low alpha/beta 
ratio of prostate cancer, the delivery of very high radiation 
doses in few fractions, may even improve the therapeutic 
ratio in the treatment of this disease. This phase II study was 
aimed to evaluate the efficacy and toxicity of SBRT in a 
series of patients with low or intermediate risk prostate 
cancer. 
 
Material and Methods: Biopsy confirmed prostate cancer 
patients were enrolled in this phase II trial, provided that 
they had the following characteristics: iPSA < 20 ng/ml, 
Gleason Score < 7, IPSS < 7. The treatment schedule was 35 
Gy in 5 fractions, delivered every other day with VMAT 
technology in FFF modality. Toxicity was recorded according 
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to CT-CAE criteria v3.0. Biochemical failure was calculated 
according to the Phoenix definition. 
 
Results: Between December 2011 and March 2015, 90 
patients were enrolled (53 low risk, 37 intermediate risk). 
The median age was 71 years (range 48 – 82 y). The median 
Gleason Score was 6 (range 6-7) and the median initial PSA 
was 6.9 ng/ml (range 2.7 – 17.0). Acute toxicity was mild, 
with 32.2 patients presenting a G1 urinary toxicity and 31.1% 
of patients presenting a G2 urinary toxicity, mainly 
represented by urgency, dysuria and stranguria. A rectal G1 
toxicity was found in a 15.5% of patients, while a rectal G2-
toxicity was recorded in 6.6% of patients. Regarding late 
toxicity, a G1 proctitis was recorded in 11.1% of patients and 
a G1 urinary (urgency, cystitis) in 38.8%; only 2 events of G2 
urinary toxicity were observed (transient urethral stenosis, 
resolved by a 24-hour catheterization). At a median follow up 
of 27 months (range 6 - 62 months) only two intermediate 
risk patients experienced a biochemical failure (22 and 24 
months after radiotherapy, respectively). PET Choline 
revealed a nodal recurrence in one patient who underwent a 
further stereotactic radiotherapy and is now free of disease. 
In the other patient a local recurrence was diagnosed, 
associated to bone progression (rib), therefore the patient 
started ADT. Compliance to treatment was good, as reported 
by the EPIC questionnaires, which revealed a slight worsening 
in the urinary domains during treatment, with a return to 
baseline three months after treatment. 
 
Conclusion: Stereotactic Body Radiotherapy seems to be a 
valid therapeutic option in low and intermediate risk prostate 
cancer patients, warranting an adequate control of disease, 
with mild toxicity profiles and good patient-reported quality 
of life perception.  
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Purpose or Objective: The treatment for locally advanced 
prostate cancer is still a controversial issue and 
multimodality treatment can lead to treatment optimization. 
The aim of this study is to describe technical and clinical 
aspects of intra-operative radiotherapy (IORT) in patients 
with locally advanced prostate cancer. 
 
Material and Methods: Between September 2005 and 
September 2015, a total of 110 patients were enrolled. The 
statistical analysis was performed in 95 patients with follow 
up > 12 months. Inclusion criteria were: patients age < 76 
years, KPS > 90, initial PSA (iPSA) > 10 ng/ml, clinical staging 
> cT2c according with TNM, probability of organ-confined 
disease < 25% according to MSKCC nomogram. Median age was 
66.9 years (range 51-83), median iPSA was 14.6 ng/ml (range 
2.0-80) and median Gleason Score (GS) was 8 (range 4-10). 
After surgical exposure of the prostate, IORT was delivered 
by a dedicated linear accelerator (Mobetron, Intraop, 
Sunnyvale, CA) with 30° beveled collimator, using an 
electron beam of 9 or 12 MeV to a total dose of 12 Gy. IORT 
was followed by radical prostatectomy and regional lymph 
node dissection. Rectal dose was measured “in vivo” by 
radio-chromic films placed on a rectal probe. All cases with 
pathological staging≥ pT3a, positive margins (R1) or 
metastatic lymph nodes (N1) received postoperative external 
beam radiotherapy (EBRT), delivered to surgical bed with 3D 
conformal technique or intensity modulated radiation 
therapy to a total dose of 46-50 Gy (2Gy/fraction). Patients 
with pT3 or pT4 disease and/or N1 received adjuvant 
hormonal therapy. 
 
Results: IORT procedure lasted in average 30 minutes (range 
15-50). No major intra- or post-operative complication 
occurred. Median dose to the anterior rectal wall was 4.32 Gy 
(range 0.06-11.3). Pathological stage was: 30 pT2, 60 pT3, 5 
pT4. 55/95 (57.9%) patients were R1 and 27/95 (28.4%) 
patients were N1. Median post operative PSA was 0.06 ng/ml 
(range 0-4). Post-operative radiotherapy was delivered to 
73/95 patients (76.8%) with pathological staging ≥ pT3a or 
R1. Hormone therapy was prescribed to 61/95 patients 
(64.2%). Acute toxicity was: 16 G2 (9 GU; 7 GI), 2 G3 (1 GU; 1 
GI). Late toxicity was: 11 G2 (5 GU, 6 GI), 4 G3 (2 GU; 2 GI). 
No G4 acute or late toxicity was observed. Four patients died 
of prostate cancer. With a median follow-up of 61.5 months 
(range 12-108), 26/95 patients experienced biochemical 
failure. Overall biochemical free survival (BFS) was 50% at 5 
years. 5 years BFS was 78% and 42 % in high and very high risk 
classes according to NCCN classification. No evidence of 
failure in the prostate surgical bed was observed. 
 
Conclusion: IORT during radical prostatectomy is a feasible 
procedure and allows to deliver safely post-operative EBRT to 
surgical bed without a significant increase of toxicity. With a 
median follow-up of 61.5 months, biochemical control seems 
to be optimal in particular for high risk patients. 
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Purpose or Objective: To evaluate toxicity, clinical outcome 
and predictive response factors in patients with prostate 
cancer (PCa) oligometastic (<2 lesions) to the bone at 
diagnosis, simultaneously treated with curative radiotherapy 
(RT) to primary tumor/prostatic bed (PB) and bone 
metastases. 
 
Material and Methods: From February 2009, 33 patients with 
oligometastatic PCa (OPC), 18 of whom previously treated 
with radical prostatectomy and pelvic lymphadenectomy, 
underwent RT at “radical” dose to bone metastases (median 
2-Gy equivalent dose, EQD2, >40 Gy, for α/β=2,2), to the 
pelvic ± lomboaortic nodes (51,8 Gy for α/β=1,5), and to the 
PB (median EQD2 72,4 Gy) or the prostate (median EQD2 88 
Gy) within the same RT course in association with androgen 
deprivation therapy (ADT). To evaluate the possible role of 
adding a local treatment (radical dose RT to all sites of 
disease) to ADT, the biochemical relapse-free survival (bRFS), 
clinical failure-free survival (CFFS) and freedom from distant 
progression (FFDP, when the disease occurred in a different 
site from that treated) were considered, starting from the 
first day of RT. 
 
Results: After a median follow-up of 20.2 months, 3 patients 
died, 1 were lost to follow-up, 2 showed in-field and 7 out-
of-field progression, 3 have ended ADT and are still free from 
any progression. Acute toxicity was very mild with no Grade 
>2 events, and only 2 serious late events, 1 G3 and 1 G4 late 
urinary toxicity, only in the hypofractionated postoperative 
cohort. With respect to bone irradiation, no Grade ≥ 1 
toxicity were reported. Median bRFS, CFFS and FFDP were 
15,8 months, 16,9 months and 17,2 months, respectively. 
When considering FFDP, the most significant clinical end-
point to evaluate the role of RT in this subset of patients, the 
most predictive factors were: PSA at diagnosis (iPSA>24,2 
ng/ml, most-informative cut-off, AUC 77%, p=0,008) (HR=4.2, 
p=0,05), 2 vs 1 metastasis (HR=2.87, p=0,1), and no previous 
prostatectomy (HR=3,19, p=0,08), while no role emerged for 
the site of metastases (pelvic or not). When stratifying 
